Recent evidence has demonstrated that acquired uniparental disomy (aUPD) is a novel mechanism by which pathogenetic mutations in cancer may be reduced to homozygosity. To help identify novel mutations in myeloproliferative neoplasms (MPN), we performed a genome wide single nucleotide polymorphism (SNP) screen to identify aUPD in 58 patients with atypical chronic myeloid leukemia (aCML; n=30), JAK2 mutation negative myelofibrosis (MF; n=18) or JAK2 mutation negative polycythemia vera (PV; n=10). Stretches of homozygous, copy neutral SNP calls >20Mb were seen in 10 (33%) aCML, 1 (6%) MF but absent in PV. In total seven different chromosomes were involved with 7q and 11q each affected in 10% of aCML cases. CBL mutations were identified in all three cases with 11q aUPD and analysis of 574 additional MPNs revealed a total of 27 CBL variants in 26 patients with aCML, myelofibrosis or chronic myelomonocytic leukemia. Most variants were missense substitutions in the RING or linker domains that abrogated CBL ubiquitin ligase activity and conferred a proliferative advantage to 32D cells overexpressing FLT3.
Introduction
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by over proliferation of one or more myeloid cell lineages in the bone marrow and increased numbers of mature and immature myeloid cells in the peripheral blood. Excess proliferation is frequently associated with splenomegaly, cardiovascular complications as well as increased risk of transformation to acute leukemia. MPNs are categorized into subtypes based on specific morphological, hematological and laboratory parameters, the best characterized being the four so called 'classic' MPNs -polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF) and chronic myeloid leukemia (CML) 1 . In addition, several 'atypical' MPNs are recognized, some of which show both dysplastic and proliferative features, such as atypical, BCR-ABL negative CML (aCML) 2 .
MPNs are associated with acquired, activating mutations or gene fusions of tyrosine kinases, abnormalities that are believed to be critical drivers of excess proliferation as a result of deregulated or constitutive signaling 3 . The two most prominent examples are BCR-ABL in CML 4 and the V617F JAK2 mutation in PV, ET and MF [5] [6] [7] [8] , but more than 40 variant tyrosine kinase fusions have been identified in MPNs as well as other mutations in JAK2 and FLT3
2
. Activating mutations have been described in components that signal upstream (e.g. MPL) or downstream (e.g. NRAS) of tyrosine kinases 9;10 , however the molecular pathogenesis of the majority of atypical MPNs and approximately 50% of ET and MF cases remains obscure.
V617F JAK2 was initially identified by several different routes, one of which was based on the observation that many PV patients show evidence of acquired uniparental disomy (aUPD) at chromosome 9p 11;12 . Regions of aUPD exhibit loss of heterozygosity (LOH) compared to constitutional DNA without change of copy number and arise by mitotic recombination followed by selection for one of the products. Following the initial observations in PV, it has emerged that aUPD is common in both hematological and epithelial malignancies, and is associated with known oncogenic changes in a variety of genes within the affected regions 13 . In this study we set out to determine if aUPD characterizes MPNs of unknown molecular
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Patients and Methods
Patients. Peripheral blood or bone marrow samples were received from patients diagnosed with an MPN or other hematologic malignancy according to standard morphological, hematologic and laboratory criteria. Clinical data was available from a subset of these cases. The study was approved by the Internal Review Boards from participating institutions and informed consent was provided according to the Declaration of Helsinki.
SNP array analysis. DNA labelling and hybridization to Affymetrix 50k XbaI chips was performed at the Deutsches Ressourcenzentrum für Genomforschung GmbH (RZPD, Berlin, Germany). Raw data was imported into the Affymetrix GeneChip®
Operating Software, analyzed using Affymetrix GeneChip® Genotyping Analysis Software (GTYPE 4.1) and copy number analysis tool (CNAT). Data was exported to custom designed spreadsheets which display loss of heterozygosity and copy number changes in ideogram format. Data was also analyzed using Affymetrix Genotyping Console (version 2.1). Overall a median of 98.2% (range 91.5 -99.6) SNPs gave readable calls.
Mutation analysis. Detection of mutations by high resolution melting (HRM)
analysis was performed as described 14 tgtggtttcactttaaaccctgga-3') and CBL_i8r (5'-gccaggccaccccttgtatc-3') and for CBL exon 9 were CBL_i8f (5'-ggcctggcttttgggttagg-3') and CBL_i9r (5'-cacaatggattttgccagtctcc-3'). CBL reverse-transcriptase PCR (RT-PCR) was performed on random hexamer-reverse transcribed RNA using primers CBLe7F: 5'-gaatcctgatctgactggcttatg-3' and CBLe10R 5'-gctgcggcagaaggtcaagt-3'. Other primer sequences are available on request.
Microsatellite analysis. DNA samples were amplified with a series of fluorescently labeled primer pairs flanking highly polymorphic microsatellite markers on chromosome 11q as described 10 . aUPD was scored if four or more consecutive markers encompassing CBL were homozygous without change in allelic copy number (P<0.05 of this occurring in the absence of aUPD based on published rates of heterozygosity. Copy number at 11q was estimated by multiplex ligation probe amplification (MLPA) using the Marfan probeset 1 (P065, MRC Holland, Amsterdam,
The Netherlands), a kit that contains four 11q control probes including one at 11q23.3.
Constructs. pMY-wtCBL and pMY-CBLR420Q express wild type and R420Q CBL, respectively, along with green fluorescent protein (GFP) 15 . Other CBL mutant constructs were derived from pMY-wtCBL using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). pAL/FLT3 and pCMV-HA ubiquitin have also been described previously 15 .
Cell lines. The IL-3-dependent murine myeloid cell 32Dcl3 (32D) was purchased from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig, Germany) and was maintained in 90% RPMI 1640 medium with 10%
foetal bovine serum (FBS) and 10% WEHI-3B conditioned medium (WEHI). All cells were maintained in a humidified incubator at 37°C and 5% carbon dioxide. 32D cells were stably transduced by electroporation with wt-FLT3 in a pAL vector as previously described 16 and maintained in 15ng/ml blastocidin (Invitrogen, Paisley UK). The Platinum-E (Plat-E) retrovirus packaging cell line 17 was transfected using the calcium phosphate method with 5μg CBL construct DNA: 10 6 32D/wtFLT3 cells were co-cultivated with the Plat-E cells for 48hrs in a volume of 2ml (50% RPMI, 50% DMEM, 10% FBS, 5% WEHI). GFP positive cells were flow sorted to highest possible purity using a BD FACSAria™ cell sorter (Becton Dickinson, Stanford, running to a telomere without change in copy number (Figure 1a) . Such large regions are uncommon in normal individuals 19 . Strikingly, we found that aUPD was common in aCML with 10 (33%) of cases affected. In contrast, aUPD was only seen in a single case of MF and was not seen in other patient subgroups. In total seven different chromosomes were affected, with abnormalities at 7q and 11q each seen recurrently in 10% of aCML cases. The affected regions ranged in size from 29Mb to a complete copy of chromosome 13 ( Table 1) .
Association between aUPD and known acquired oncogenic mutations. Although Figure 1d ). Candidate genes for the abnormalities at 17q and 21q include NF1 and RUNX1, respectively, however these were not investigated.
11q aUPD is associated with CBL mutations. Next, we focused our analysis on the two recurrent regions of aUPD at 7q and 11q. Because of the strong association between MPNs and aberrant tyrosine kinase signaling, we analyzed genes encoding tyrosine kinases and associated signaling components. The minimally affected region at chromosome 7q contains three tyrosine kinases: MET, EPHA1 and EPHB6. We fully sequenced the coding exons of these genes in the three cases with 7q aUPD and two normal controls but found no abnormalities. Similarly we found no sequence changes in exons 11-17 of BRAF, a gene encoding a downstream component of RAS signalling that is mutated in malignant melanoma and other cancers. 20 There are no tyrosine kinase genes on chromosome 11q and although there are several genes encoding signal transduction components, CBL stood out as a known oncogene that negatively regulates tyrosine kinase signaling 21 . Sequencing of CBL in the three 11q Tables 2 and 3 ). To ensure that we were not missing mutations elsewhere in the gene we analyzed all coding exons in 70 CBL mutation negative aCML or unclassified, CML-like MPN cases by high resolution melt (HRM) analysis but failed to detect any further sequence changes apart from known polymorphisms. Similarly, no mutations in CBLB exons 9 or 10 or CBLC exons 7 and 8 (the exons that correspond to CBL exons 8 and 9) were identified. The activity of BCR-ABL is known to increase during progression of CML from chronic phase to blast crisis 22 and we speculated that abrogation of CBL activity might be at least partially responsible for this increase. HRM analysis of CBL exons 8 and 9 in blast crisis cases (n=31), however, failed to reveal any mutations.
Of the 27 CBL variants, 21 (78%) were missense substitutions affecting 12 amino acids (15 different substitutions), 5 (19%) were candidate splicing abnormalities and one (3%) produced a stop codon (Table 3) . Most of the changes were novel, although 4 cases had R420Q as previously identified in a single case of AML 15 . Apart from N454D, all residues affected by missense mutations were completely conserved in CBL orthologues as well as the two other human CBL family members ( Figure 3) .
The mutation to a stop codon was found in a patient (UPN 9) who also had the Y371H variant; PCR across the affected regions and sequencing indicated that the two changes were on different alleles. The association between CBL mutations and UPD. To examine the association between CBL mutations and aUPD in more detail we performed microsatellite analysis on all mutated cases using 9 polymorphic markers spanning chromosome Figure 5 ). We performed multiplex ligation probe amplification (MLPA) analysis to determine if the observed homozygosity was a consequence of a deletion but no copy number changes were detected (data not shown) and therefore it is likely that homozygosity arose by aUPD.
The number of mutated alleles estimated by sequencing was concordant with the microsatellite analysis in 20 cases ( Figure 5 ). Of those that were discordant, UPN 6 and UPN 25 had significant tracts of 11q homozygosity but had a monoallelic CBL mutation whereas UPN 10 and UPN 16 did not show 11q homozygosity but had clear biallelic CBL mutations. The reason for these discrepant cases is unclear, but it is possible that the aUPD seen in UPN 6 and UPN 25 targeted another gene at 11q prior to acquisition of the CBL mutation. Homozygosity for the CBL mutations in the absence of 11q aUPD in UPN 10 and UPN 16 might be explained by a subcytogenetic deletion of one allele.
Correlation between CBL mutations and clinical features. We compared clinical and hematological features in patients with or without CBL mutations, restricting the analysis to cases with aCML, MF and CMML since these were the subgroups in which CBL mutations were most commonly found. Patients with CBL mutations had a shorter overall survival and progression-free survival compared to mutation negative cases (overall survival: 33 months versus 39 months; progression-free survival: 22 months versus 32 months) but the differences were not significant ( Figure 6 ).
Similarly there was no significant difference in gender distribution, age and standard hematological parameters between mutation positive and mutation negative cases and no differences emerged when individual disease entities were considered.
Transforming activities of CBL mutants. We determined if selected CBL variants had oncogenic activity by testing if they could transform the interleukin-3 (IL-3) dependent cell line 32D to growth factor independence in conjunction with overexpression of wild type FLT3, as has been described previously for R420Q 15 .
We found that S376F, H398Y, P417A and R420Q alone each conferred a degree of growth factor independence to 32D cells, but this effect was considerably enhanced in 32Ds that overexpressed wild type FLT3. In contrast, wild type CBL conferred no growth advantage either with or without FLT3 overexpression. The N454D change was not transforming, indicating that it is probably a rare polymorphism or a pathogenetically unimportant passenger mutation ( Figure 7 ). Reproducible differences in survival between the different mutants were seen, as illustrated on Figure 8A .
Abrogation of E3 ubiquitin ligase activity. It has been shown that FLT3 physically associates with CBL and that, upon ligand stimulation, FLT3 is rapidly ubiquitinylated by wild type but not R420Q CBL 15 . We found that transforming activity correlated directly with the ubiquitin ligase activity of the CBL variants, as assayed by their ability to transfer HA-tagged ubiquitin to FLT3 following stimulation with FLT3 ligand. The S376F, H398Y, P417A and R420Q mutants showed loss of ubiquitin ligase activity, whereas N454D was comparable to wild type CBL ( Figure   8B ).
Discussion
The initial aim of our study was to identify large regions of aUPD and therefore we undertook a relatively low resolution genome scan using 50k SNP arrays. Since we did not have constitutional DNA available from most of our cases, we were not able to unambiguously determine whether the extended blocks of homozygosity that we observed were a consequence of aUPD, constitutional UPD or autozygosity due to consaguinity, however we used a very conservative definition of candidate aUPD regions (at least 20Mb of homozygous SNPs calls running to a telomere) and therefore expected that most or all would be acquired. We found that aUPD was relatively common in aCML, but was uncommon in other MPNs that were negative for known mutations, plus also CML blast crisis and CLL. Six distinct regions of aUPD were identified in aCML, indicating substantial genetic heterogeneity in the genesis of this disorder. However we identified two recurrent regions of aUPD at 7q
and 11q that were each seen in 10% of cases indicating the presence of common molecular abnormalities. that CBL mutations will also prove to be common in this disease. Indeed, 7 of 12 MDS cases with aUPD at 11q were recently shown to harbour CBL mutations. 29 There are two other human CBL family members, CBLB and CBLC, but we did not identify aUPD in the regions containing these genes and did not detect any mutations of the linker/RING domain of CBLB.
We identified a total of 15 different CBL missense mutations affecting 12 residues (Table 2, Figure 3 ). Mutations of some of these residues, e.g. Y371, C381, H398 and W408 have been analyzed previously in a study which concluded that loss of E3 ubiquitin ligase activity and concomitant impairment of EGFR internalization by 30 . Although the precise amino acid substitutions we identified were different from those studied, we found that mutations in both the RING finger and linker regions conferred autonomous growth to 32D/wt-FLT3 cells, consistent with a causal relationship to the MPN phenotype. The fact that one mutation (N454D) was not transforming emphasizes the importance of functional analysis to distinguish driver mutations from irrelevant passengers or infrequent polymorphisms 31 . Notably, this mutation was only weakly conserved between species, in contrast to all other missense mutations that affected highly conserved residues and are therefore likely to be functionally significant. . Whilst it is possible that overt hematological disease might have been induced by a homozygous knock-in mutant, these findings suggest that CBL mutations may not be solely responsible for a full MPN phenotype.
The nature of any co-operating abnormalities remains largely obscure. Our results
show that overexpression of a tyrosine kinase can co-operate with CBL mutants to promote transformation, however we failed to identify any kinase that was consistently overexpressed in mutation positive cases by tyrosine kinase expression profiling (data not shown). One CBL mutation positive case, however, also tested positive for 7q UPD by SNP array suggesting that these two abnormalities may complement each other. A CBL mutation resulting in skipping of exon 8 has also been identified in a murine model of NUP98-HOXD13 on progression from MDS to AML 38 , further corroborating the theory that acute leukemia arises from complementary mutations, one of which inhibits differentiation, and a second (in this case CBL) which enhances proliferation or inhibits apoptosis.
The fact that many CBL mutations are associated with aUPD strongly suggests that clones with homozygous mutations have a selective advantage over those that are heterozygous. This contrasts with the prevailing view that transforming CBL RING finger and linker region mutants act in a dominant negative fashion. Although it is conceivable that another, unknown locus on 11q is the target of aUPD, the finding of one case with a Y371H mutation and a stop codon on opposite alleles strongly suggests that homozygous CBL mutations do indeed confer a direct selective advantage. Since we did not screen the entire gene for mutations, it is possible that other cases with heterozygous mutations may also be functionally homozygous due to premature stop codons on the other allele. Alternatively, heterozygosity in these cases may only be apparent due to variable proportions of background normal cells that are not part of the malignant clone. Although the non-transforming N454D mutant was heterozygous, two cases with heterozygous R420Q were observed and thus absence of
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homozygosity cannot be used to infer the presence of an irrelevant, non-transforming sequence variant.
In summary, we have found that oncogenic CBL mutations are acquired in a subset of hematologically related, poor prognosis MPNs. Our findings further strengthen the notion that MPNs are primarily 'tyrosine kinopathies', i.e. diseases caused by aberrant activation of proliferation and survival pathways as a consequence of mutations that either directly or indirectly promote excess tyrosine kinase signalling. In view of the fact that tyrosine kinases are such good drug targets, the possibility that CBL-mutated cases might be amenable to therapeutic inhibition is clearly attractive. 
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